Andriy Derkach

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8224170/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Chemotherapy and COVID-19 Outcomes in Patients With Cancer. Journal of Clinical Oncology, 2020, 38, 3538-3546.	1.6	195
2	Identifying biomarkers of dietary patterns by using metabolomics. American Journal of Clinical Nutrition, 2017, 105, 450-465.	4.7	168
3	Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances, 2021, 5, 1552-1564.	5.2	102
4	Robust and Powerful Tests for Rare Variants Using Fisher's Method to Combine Evidence of Association From Two or More Complementary Tests. Genetic Epidemiology, 2013, 37, 110-121.	1.3	83
5	The Consortium of Metabolomics Studies (COMETS): Metabolomics in 47 Prospective Cohort Studies. American Journal of Epidemiology, 2019, 188, 991-1012.	3.4	81
6	Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure. Blood Advances, 2020, 4, 2866-2870.	5.2	81
7	Clonal hematopoiesis is associated with risk of severe Covid-19. Nature Communications, 2021, 12, 5975.	12.8	81
8	Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. Nature Communications, 2021, 12, 1861.	12.8	68
9	Cigarette smoking behaviour and blood metabolomics. International Journal of Epidemiology, 2016, 45, 1421-1432.	1.9	63
10	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. JAMA Oncology, 2021, 7, 862.	7.1	63
11	Pooled Association Tests for Rare Genetic Variants: A Review and Some New Results. Statistical Science, 2014, 29, .	2.8	60
12	Effects of dietary sodium on metabolites: the Dietary Approaches to Stop Hypertension (DASH)–Sodium Feeding Study. American Journal of Clinical Nutrition, 2017, 106, 1131-1141.	4.7	55
13	Prospective Investigation of Serum Metabolites, Coffee Drinking, Liver Cancer Incidence, and Liver Disease Mortality. Journal of the National Cancer Institute, 2020, 112, 286-294.	6.3	53
14	Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. British Journal of Cancer, 2016, 115, 1087-1095.	6.4	52
15	Plasmacytoid dendritic cell expansion defines a distinct subset of <i>RUNX1</i> -mutated acute myeloid leukemia. Blood, 2021, 137, 1377-1391.	1.4	51
16	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematology,the, 2021, 8, e422-e432.	4.6	50
17	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. Blood Cancer Discovery, 2020, 1, 234-243.	5.0	46
18	Prospective serum metabolomic profiling of lethal prostate cancer. International Journal of Cancer, 2019, 145, 3231-3243.	5.1	43

ANDRIY DERKACH

#	Article	IF	CITATIONS
19	Habitual sleep and human plasma metabolomics. Metabolomics, 2017, 13, 1.	3.0	36
20	A Comprehensive Analysis of Nuclear-Encoded Mitochondrial Genes in Schizophrenia. Biological Psychiatry, 2018, 83, 780-789.	1.3	35
21	Associations between metabolites and pancreatic cancer risk in a large prospective epidemiological study. Gut, 2020, 69, 2008-2015.	12.1	33
22	Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. British Journal of Haematology, 2022, 196, 105-109.	2.5	30
23	Serum Metabolomic Profiling of All-Cause Mortality: A Prospective Analysis in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study Cohort. American Journal of Epidemiology, 2018, 187, 1721-1732.	3.4	29
24	Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. Nature Communications, 2021, 12, 5172.	12.8	27
25	A Hypothesis-Driven Association Study of 28 Nuclear-Encoded Mitochondrial Genes with Antipsychotic-Induced Weight Gain in Schizophrenia. Neuropsychopharmacology, 2014, 39, 1347-1354.	5.4	26
26	High Dimensional Mediation Analysis With Latent Variables. Biometrics, 2019, 75, 745-756.	1.4	25
27	Pre-diagnostic Serum Metabolomic Profiling of Prostate Cancer Survival. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 853-859.	3.6	21
28	Associations between IgG reactivity to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) antigens and Burkitt lymphoma in Ghana and Uganda case-control studies. EBioMedicine, 2019, 39, 358-368.	6.1	20
29	Association of Body Mass Index with Fecal Microbial Diversity and Metabolites in the Northern Finland Birth Cohort. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2289-2299.	2.5	20
30	Power Analysis for Genetic Association Test (PAGEANT) provides insights to challenges for rare variant association studies. Bioinformatics, 2018, 34, 1506-1513.	4.1	18
31	Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia and Lymphoma, 2021, 62, 3394-3401.	1.3	17
32	The association of sleep with metabolic pathways and metabolites: evidence from the Dietary Approaches to Stop Hypertension (DASH)—sodium feeding study. Metabolomics, 2019, 15, 48.	3.0	15
33	Patterns of Human Leukocyte Antigen Class I and Class II Associations and Cancer. Cancer Research, 2021, 81, 1148-1152.	0.9	15
34	Score tests for association under response-dependent sampling designs for expensive covariates. Biometrika, 2015, 102, 988-994.	2.4	13
35	Multicenter evaluation of efficacy and toxicity of venetoclaxâ€based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. American Journal of Hematology, 2022, 97, .	4.1	13
36	Therapeutic Efficacy of Combined JAK1/2, Pan-PIM, and CDK4/6 Inhibition in Myeloproliferative Neoplasms. Clinical Cancer Research, 2021, 27, 3456-3468.	7.0	12

ANDRIY DERKACH

#	Article	IF	CITATIONS
37	Genetic Analysis Workshop 18 single-nucleotide variant prioritization based on protein impact, sequence conservation, and gene annotation. BMC Proceedings, 2014, 8, S11.	1.6	10
38	Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twiceâ€weekly carfilzomib (45 and 56 mg/m ²) in combination with lenalidomide and dexamethasone. American Journal of Hematology, 2021, 96, E193-E196.	4.1	10
39	BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation. Blood, 2022, 139, 3630-3646.	1.4	9
40	Evaluation of gene-based association tests for analyzing rare variants using Genetic Analysis Workshop 18 data. BMC Proceedings, 2014, 8, S9.	1.6	7
41	Metabolomic Profiling of Serum Retinol in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. Scientific Reports, 2017, 7, 10601.	3.3	7
42	Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leukemia and Lymphoma, 2021, 62, 1940-1948.	1.3	7
43	Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience. Blood, 2021, 138, 1644-1644.	1.4	7
44	Nutrition perceptions, needs and practices among patients with plasma cell disorders. Blood Cancer Journal, 2022, 12, 70.	6.2	7
45	Group testing in mediation analysis. Statistics in Medicine, 2020, 39, 2423-2436.	1.6	6
46	Serum antibody response in patients with philadelphia-chromosome positive or negative myeloproliferative neoplasms following vaccination with SARS-CoV-2 spike protein messenger RNA (mRNA) vaccines. Leukemia, 2021, 35, 3578-3580.	7.2	6
47	Polygenic risk score for the prediction of breast cancer is related to lesser terminal duct lobular unit involution of the breast. Npj Breast Cancer, 2020, 6, 41.	5.2	5
48	Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Clinical Cancer Research, 2021, 27, 2111-2118.	7.0	5
49	Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. Blood Advances, 2022, 6, 3433-3439.	5.2	5
50	Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. Haematologica, 2022, 107, 284-286.	3.5	4
51	Immuneâ€related conditions and cancerâ€specific mortality among older adults with cancer in the United States. International Journal of Cancer, 2022, 151, 1216-1227.	5.1	4
52	African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients Journal of Clinical Oncology, 2022, 40, 8045-8045.	1.6	4
53	Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. Blood, 2020, 136, 18-20.	1.4	3
54	Breast Cancer Risk in Women from Ghana Carrying Rare Germline Pathogenic Mutations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1593-1601.	2.5	3

ANDRIY DERKACH

#	Article	IF	CITATIONS
55	Subset testing and analysis of multiple phenotypes. Genetic Epidemiology, 2019, 43, 492-505.	1.3	2
56	Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy. Leukemia Research, 2021, 106, 106569.	0.8	2
57	Whole-Genome Sequencing Reveals Evidence of Two Biologically and Clinically Distinct Entities: Progressive <i>Versus</i> Stable Myeloma Precursor Disease. Blood, 2020, 136, 47-48.	1.4	2
58	Outcomes of Patients with COVID-19 from a Specialized Cancer Care Emergency Room. Cancer Investigation, 2022, 40, 17-25.	1.3	2
59	Copy Number Signatures Predict Chromothripsis and Poor Clinical Outcome in Newly Diagnosed Multiple Myeloma Patients. Blood, 2020, 136, 52-53.	1.4	2
60	Association of Patient Activity Bioprofiles with Hrqol and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients. Blood, 2020, 136, 26-28.	1.4	2
61	P-042: Sustained minimal residual disease negativity in Multiple Myeloma is impacted positively by stool butyrate and healthier plant forward diets. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S61.	0.4	2
62	Hypofibrinogenemia and disseminated intravascular coagulation rarely complicate treatment-naÃ ⁻ ve acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2497-2501.	1.3	1
63	A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study. Blood, 2021, 138, 4759-4759.	1.4	1
64	Venetoclax Therapy for Relapsed and Treatment Refractory AML: Clinical Outcomes and Molecular Predictors. Blood, 2020, 136, 47-48.	1.4	1
65	VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup. Blood, 2020, 136, 37-38.	1.4	1
66	Evaluating serum-free light chain ratio as a biomarker for multiple myeloma Journal of Clinical Oncology, 2022, 40, 8047-8047.	1.6	1
67	P-152: Providing nutritional guidance for patients with plasma cell disorders – a missed opportunity for hematologists and oncologists?. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S118-S119.	0.4	0
68	The Genomic Landscape of Waldenström Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations. Blood, 2021, 138, 2394-2394.	1.4	0
69	Clinical and Genomic Characterization of Secondary Acute Myeloid Leukemia with Mixed Phenotype. Blood, 2021, 138, 687-687.	1.4	0
70	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 18-19.	1.4	0
71	Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls. Blood, 2020, 136, 44-45.	1.4	0
72	Clinical Outcomes of Acute Myeloid Leukemia Patients Bridged to Allogeneic Stem Cell Transplant By Venetoclax Combination Therapy. Blood, 2020, 136, 16-17.	1.4	0

#	Article	IF	CITATIONS
73	Impact of Additional Cytogenetic Abnormalities and Complex Karyotype on Event-Free Survival in Acute Promyelocytic Leukemia: Analysis from a Single Academic Center Plus the APML4 Study. Blood, 2020, 136, 34-35.	1.4	0
74	Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Blood, 2020, 136, 50-51.	1.4	0
75	Clinical efficacy of daratumumab (DARA)-based second line therapy after DARA-containing and DARA-free induction therapies in multiple myeloma: A single center experience Journal of Clinical Oncology, 2022, 40, e20005-e20005.	1.6	0